The use of the VEGF inhibitor Bevacizumab or the use of intravenous immunoglobulins is based on observations of increased vascular permeability, co-occurrence with increased VEGF, TNF-a levels, and the high proportion of patients with monoclonal gammopathy. This evidence concerns the gene VEGFA and monoclonal gammopathy.